The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Synopsis
Eosinophilic esophagitis (EoE, also spelled eosinophilic oesophagitis), also known as allergic oesophagitis, is an allergic inflammatory condition of the esophagus that involves eosinophils, a type of white blood cell. Symptoms are swallowing difficulty, food impaction, vomiting, and heartburn.
Eosinophilic esophagitis was first described in children but also occurs in adults. The condition is not well understood, but food allergy may play a significant role. The treatment may consist of removal of known or suspected triggers and medication to suppress the immune response.
This report studies the eosinophilic esophagitis drug market.
The global Eosinophilic Esophagitis Drug market was valued at US$ 129.8 million in 2023 and is anticipated to reach US$ 189.7 million by 2030, witnessing a CAGR of 5.5% during the forecast period 2024-2030.
AstraZeneca, GSK and Bayer are the leading producers of eosinophilic esophagitis drug, which together account for about 80% of the market.
North America is the leading region, accounting for more than 30% of the market, followed by Europe at nearly 30%.
This report aims to provide a comprehensive presentation of the global market for Eosinophilic Esophagitis Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Eosinophilic Esophagitis Drug.
Report Scope
The Eosinophilic Esophagitis Drug market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Eosinophilic Esophagitis Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Eosinophilic Esophagitis Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
- AstraZeneca
- GSK
- Bayer
- Adare Pharmaceuticals
- DBV Technologies
- Dr. Falk Pharma
- Quorum Innovations
- Takeda
- Calypso
- Celgene
- Regeneron
Segment by Type
- Budesonide
- Fluticasone
- Others
Segment by Application
- Hospitals
- Clinics
- Drugstore
Consumption by Region
- North America (United States, Canada and Mexico)
- Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
- South America (Brazil, Argentina, Colombia, and Rest of South America)
- Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Eosinophilic Esophagitis Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Eosinophilic Esophagitis Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index
1 Eosinophilic Esophagitis Drug Market Overview
1.1 Product Overview and Scope of Eosinophilic Esophagitis Drug
1.2 Eosinophilic Esophagitis Drug Segment by Type
1.2.1 Global Eosinophilic Esophagitis Drug Market Value Comparison by Type (2024-2030)
1.2.2 Budesonide
1.2.3 Fluticasone
1.2.4 Others
1.3 Eosinophilic Esophagitis Drug Segment by Application
1.3.1 Global Eosinophilic Esophagitis Drug Market Value by Application: (2024-2030)
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Drugstore
1.4 Global Eosinophilic Esophagitis Drug Market Size Estimates and Forecasts
1.4.1 Global Eosinophilic Esophagitis Drug Revenue 2019-2030
1.4.2 Global Eosinophilic Esophagitis Drug Sales 2019-2030
1.4.3 Global Eosinophilic Esophagitis Drug Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Eosinophilic Esophagitis Drug Market Competition by Manufacturers
2.1 Global Eosinophilic Esophagitis Drug Sales Market Share by Manufacturers (2019-2024)
2.2 Global Eosinophilic Esophagitis Drug Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Eosinophilic Esophagitis Drug Average Price by Manufacturers (2019-2024)
2.4 Global Eosinophilic Esophagitis Drug Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Eosinophilic Esophagitis Drug, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Eosinophilic Esophagitis Drug, Product Type & Application
2.7 Eosinophilic Esophagitis Drug Market Competitive Situation and Trends
2.7.1 Eosinophilic Esophagitis Drug Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Eosinophilic Esophagitis Drug Players Market Share by Revenue
2.7.3 Global Eosinophilic Esophagitis Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Eosinophilic Esophagitis Drug Retrospective Market Scenario by Region
3.1 Global Eosinophilic Esophagitis Drug Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Eosinophilic Esophagitis Drug Global Eosinophilic Esophagitis Drug Sales by Region: 2019-2030
3.2.1 Global Eosinophilic Esophagitis Drug Sales by Region: 2019-2024
3.2.2 Global Eosinophilic Esophagitis Drug Sales by Region: 2025-2030
3.3 Global Eosinophilic Esophagitis Drug Global Eosinophilic Esophagitis Drug Revenue by Region: 2019-2030
3.3.1 Global Eosinophilic Esophagitis Drug Revenue by Region: 2019-2024
3.3.2 Global Eosinophilic Esophagitis Drug Revenue by Region: 2025-2030
3.4 North America Eosinophilic Esophagitis Drug Market Facts & Figures by Country
3.4.1 North America Eosinophilic Esophagitis Drug Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Eosinophilic Esophagitis Drug Sales by Country (2019-2030)
3.4.3 North America Eosinophilic Esophagitis Drug Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Eosinophilic Esophagitis Drug Market Facts & Figures by Country
3.5.1 Europe Eosinophilic Esophagitis Drug Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Eosinophilic Esophagitis Drug Sales by Country (2019-2030)
3.5.3 Europe Eosinophilic Esophagitis Drug Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Eosinophilic Esophagitis Drug Market Facts & Figures by Country
3.6.1 Asia Pacific Eosinophilic Esophagitis Drug Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Eosinophilic Esophagitis Drug Sales by Country (2019-2030)
3.6.3 Asia Pacific Eosinophilic Esophagitis Drug Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Eosinophilic Esophagitis Drug Market Facts & Figures by Country
3.7.1 Latin America Eosinophilic Esophagitis Drug Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Eosinophilic Esophagitis Drug Sales by Country (2019-2030)
3.7.3 Latin America Eosinophilic Esophagitis Drug Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Eosinophilic Esophagitis Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Eosinophilic Esophagitis Drug Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Eosinophilic Esophagitis Drug Sales by Country (2019-2030)
3.8.3 Middle East and Africa Eosinophilic Esophagitis Drug Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Eosinophilic Esophagitis Drug Sales by Type (2019-2030)
4.1.1 Global Eosinophilic Esophagitis Drug Sales by Type (2019-2024)
4.1.2 Global Eosinophilic Esophagitis Drug Sales by Type (2025-2030)
4.1.3 Global Eosinophilic Esophagitis Drug Sales Market Share by Type (2019-2030)
4.2 Global Eosinophilic Esophagitis Drug Revenue by Type (2019-2030)
4.2.1 Global Eosinophilic Esophagitis Drug Revenue by Type (2019-2024)
4.2.2 Global Eosinophilic Esophagitis Drug Revenue by Type (2025-2030)
4.2.3 Global Eosinophilic Esophagitis Drug Revenue Market Share by Type (2019-2030)
4.3 Global Eosinophilic Esophagitis Drug Price by Type (2019-2030)
5 Segment by Application
5.1 Global Eosinophilic Esophagitis Drug Sales by Application (2019-2030)
5.1.1 Global Eosinophilic Esophagitis Drug Sales by Application (2019-2024)
5.1.2 Global Eosinophilic Esophagitis Drug Sales by Application (2025-2030)
5.1.3 Global Eosinophilic Esophagitis Drug Sales Market Share by Application (2019-2030)
5.2 Global Eosinophilic Esophagitis Drug Revenue by Application (2019-2030)
5.2.1 Global Eosinophilic Esophagitis Drug Revenue by Application (2019-2024)
5.2.2 Global Eosinophilic Esophagitis Drug Revenue by Application (2025-2030)
5.2.3 Global Eosinophilic Esophagitis Drug Revenue Market Share by Application (2019-2030)
5.3 Global Eosinophilic Esophagitis Drug Price by Application (2019-2030)
6 Key Companies Profiled
6.1 AstraZeneca
6.1.1 AstraZeneca Corporation Information
6.1.2 AstraZeneca Description and Business Overview
6.1.3 AstraZeneca Eosinophilic Esophagitis Drug Sales, Revenue and Gross Margin (2019-2024)
6.1.4 AstraZeneca Eosinophilic Esophagitis Drug Product Portfolio
6.1.5 AstraZeneca Recent Developments/Updates
6.2 GSK
6.2.1 GSK Corporation Information
6.2.2 GSK Description and Business Overview
6.2.3 GSK Eosinophilic Esophagitis Drug Sales, Revenue and Gross Margin (2019-2024)
6.2.4 GSK Eosinophilic Esophagitis Drug Product Portfolio
6.2.5 GSK Recent Developments/Updates
6.3 Bayer
6.3.1 Bayer Corporation Information
6.3.2 Bayer Description and Business Overview
6.3.3 Bayer Eosinophilic Esophagitis Drug Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Bayer Eosinophilic Esophagitis Drug Product Portfolio
6.3.5 Bayer Recent Developments/Updates
6.4 Adare Pharmaceuticals
6.4.1 Adare Pharmaceuticals Corporation Information
6.4.2 Adare Pharmaceuticals Description and Business Overview
6.4.3 Adare Pharmaceuticals Eosinophilic Esophagitis Drug Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Adare Pharmaceuticals Eosinophilic Esophagitis Drug Product Portfolio
6.4.5 Adare Pharmaceuticals Recent Developments/Updates
6.5 DBV Technologies
6.5.1 DBV Technologies Corporation Information
6.5.2 DBV Technologies Description and Business Overview
6.5.3 DBV Technologies Eosinophilic Esophagitis Drug Sales, Revenue and Gross Margin (2019-2024)
6.5.4 DBV Technologies Eosinophilic Esophagitis Drug Product Portfolio
6.5.5 DBV Technologies Recent Developments/Updates
6.6 Dr. Falk Pharma
6.6.1 Dr. Falk Pharma Corporation Information
6.6.2 Dr. Falk Pharma Description and Business Overview
6.6.3 Dr. Falk Pharma Eosinophilic Esophagitis Drug Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Dr. Falk Pharma Eosinophilic Esophagitis Drug Product Portfolio
6.6.5 Dr. Falk Pharma Recent Developments/Updates
6.7 Quorum Innovations
6.6.1 Quorum Innovations Corporation Information
6.6.2 Quorum Innovations Description and Business Overview
6.6.3 Quorum Innovations Eosinophilic Esophagitis Drug Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Quorum Innovations Eosinophilic Esophagitis Drug Product Portfolio
6.7.5 Quorum Innovations Recent Developments/Updates
6.8 Takeda
6.8.1 Takeda Corporation Information
6.8.2 Takeda Description and Business Overview
6.8.3 Takeda Eosinophilic Esophagitis Drug Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Takeda Eosinophilic Esophagitis Drug Product Portfolio
6.8.5 Takeda Recent Developments/Updates
6.9 Calypso
6.9.1 Calypso Corporation Information
6.9.2 Calypso Description and Business Overview
6.9.3 Calypso Eosinophilic Esophagitis Drug Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Calypso Eosinophilic Esophagitis Drug Product Portfolio
6.9.5 Calypso Recent Developments/Updates
6.10 Celgene
6.10.1 Celgene Corporation Information
6.10.2 Celgene Description and Business Overview
6.10.3 Celgene Eosinophilic Esophagitis Drug Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Celgene Eosinophilic Esophagitis Drug Product Portfolio
6.10.5 Celgene Recent Developments/Updates
6.11 Regeneron
6.11.1 Regeneron Corporation Information
6.11.2 Regeneron Eosinophilic Esophagitis Drug Description and Business Overview
6.11.3 Regeneron Eosinophilic Esophagitis Drug Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Regeneron Eosinophilic Esophagitis Drug Product Portfolio
6.11.5 Regeneron Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Eosinophilic Esophagitis Drug Industry Chain Analysis
7.2 Eosinophilic Esophagitis Drug Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Eosinophilic Esophagitis Drug Production Mode & Process
7.4 Eosinophilic Esophagitis Drug Sales and Marketing
7.4.1 Eosinophilic Esophagitis Drug Sales Channels
7.4.2 Eosinophilic Esophagitis Drug Distributors
7.5 Eosinophilic Esophagitis Drug Customers
8 Eosinophilic Esophagitis Drug Market Dynamics
8.1 Eosinophilic Esophagitis Drug Industry Trends
8.2 Eosinophilic Esophagitis Drug Market Drivers
8.3 Eosinophilic Esophagitis Drug Market Challenges
8.4 Eosinophilic Esophagitis Drug Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
